Wang Likun, Wu Xueliang, Tian Ruoxi, Ma Hongqing, Jiang Zekun, Zhao Weixin, Cui Guoqing, Li Meng, Hu Qinsheng, Yu Xiangyang, Xu Wengui
Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Department of Molecular Imaging and Nuclear Medicine, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Front Oncol. 2023 Feb 22;13:1133008. doi: 10.3389/fonc.2023.1133008. eCollection 2023.
To develop and validate magnetic resonance imaging (MRI)-based pre-Radiomics and delta-Radiomics models for predicting the treatment response of local advanced rectal cancer (LARC) to neoadjuvant chemoradiotherapy (NCRT).
Between October 2017 and August 2022, 105 LARC NCRT-naïve patients were enrolled in this study. After careful evaluation, data for 84 patients that met the inclusion criteria were used to develop and validate the NCRT response models. All patients received NCRT, and the post-treatment response was evaluated by pathological assessment. We manual segmented the volume of tumors and 105 radiomics features were extracted from three-dimensional MRIs. Then, the eXtreme Gradient Boosting algorithm was implemented for evaluating and incorporating important tumor features. The predictive performance of MRI sequences and Synthetic Minority Oversampling Technique (SMOTE) for NCRT response were compared. Finally, the optimal pre-Radiomics and delta-Radiomics models were established respectively. The predictive performance of the radionics model was confirmed using 5-fold cross-validation, 10-fold cross-validation, leave-one-out validation, and independent validation. The predictive accuracy of the model was based on the area under the receiver operator characteristic (ROC) curve (AUC).
There was no significant difference in clinical factors between patients with good and poor reactions. Integrating different MRI modes and the SMOTE method improved the performance of the radiomics model. The pre-Radiomics model (train AUC: 0.93 ± 0.06; test AUC: 0.79) and delta-Radiomcis model (train AUC: 0.96 ± 0.03; test AUC: 0.83) all have high NCRT response prediction performance by LARC. Overall, the delta-Radiomics model was superior to the pre-Radiomics model.
MRI-based pre-Radiomics model and delta-Radiomics model all have good potential to predict the post-treatment response of LARC to NCRT. Delta-Radiomics analysis has a huge potential for clinical application in facilitating the provision of personalized therapy.
开发并验证基于磁共振成像(MRI)的放射组学前期模型和差异放射组学模型,以预测局部晚期直肠癌(LARC)对新辅助放化疗(NCRT)的治疗反应。
2017年10月至2022年8月期间,105例未接受过NCRT的LARC患者纳入本研究。经过仔细评估,84例符合纳入标准患者的数据用于开发和验证NCRT反应模型。所有患者均接受NCRT,并通过病理评估对治疗后反应进行评估。我们手动分割肿瘤体积,并从三维MRI中提取105个放射组学特征。然后,采用极端梯度提升算法评估并纳入重要的肿瘤特征。比较MRI序列和合成少数过采样技术(SMOTE)对NCRT反应的预测性能。最后,分别建立最佳放射组学前期模型和差异放射组学模型。使用五折交叉验证、十折交叉验证、留一法验证和独立验证来确认放射组学模型的预测性能。模型的预测准确性基于受试者工作特征(ROC)曲线下面积(AUC)。
反应良好和反应较差的患者之间临床因素无显著差异。整合不同的MRI模式和SMOTE方法提高了放射组学模型的性能。放射组学前期模型(训练AUC:0.93±0.06;测试AUC:0.79)和差异放射组学模型(训练AUC:0.96±0.03;测试AUC:0.83)对LARC的NCRT反应均具有较高的预测性能。总体而言,差异放射组学模型优于放射组学前期模型。
基于MRI的放射组学前期模型和差异放射组学模型在预测LARC对NCRT的治疗后反应方面均具有良好潜力。差异放射组学分析在促进个性化治疗提供方面具有巨大的临床应用潜力。